LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens

about

LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens

Item

http://www.wikidata.org/entity/Q58572512

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

LIGHT/TNFSF14 as a New Biomark ...... eriencing Therapeutic Regimens

@en

LIGHT/TNFSF14 as a New Biomark ...... eriencing Therapeutic Regimens

@nl

type

Item

label

LIGHT/TNFSF14 as a New Biomark ...... eriencing Therapeutic Regimens

@en

LIGHT/TNFSF14 as a New Biomark ...... eriencing Therapeutic Regimens

@nl

prefLabel

LIGHT/TNFSF14 as a New Biomark ...... eriencing Therapeutic Regimens

@en

LIGHT/TNFSF14 as a New Biomark ...... eriencing Therapeutic Regimens

@nl

P1476

LIGHT/TNFSF14 as a New Biomark ...... eriencing Therapeutic Regimens

@en

P2093

Anna Mestice

http://www.w3.org/2001/XMLSchema#string

Giacomina Brunetti

http://www.w3.org/2001/XMLSchema#string

Giorgina Specchia

http://www.w3.org/2001/XMLSchema#string

Giuseppina Storlino

http://www.w3.org/2001/XMLSchema#string

Graziana Colaianni

http://www.w3.org/2001/XMLSchema#string

Lorenzo Sanesi

http://www.w3.org/2001/XMLSchema#string

Luciana Lippo

http://www.w3.org/2001/XMLSchema#string

Maria Felicia Faienza

http://www.w3.org/2001/XMLSchema#string

Maria Grano

http://www.w3.org/2001/XMLSchema#string

Paola Curci

http://www.w3.org/2001/XMLSchema#string

P2860

LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator

The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.

Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

Advances in the understanding of myeloma bone disease and tumour growth.

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.

International staging system for multiple myeloma.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

P304

2459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2018.02459

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30405638

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

6206078

http://www.w3.org/2001/XMLSchema#string